Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population

General Hospital Psychiatry

Volumn 34, Issue 5, 2012, Pages 571-577

  Yang, Zhenxing ^a   Ma, Xiaohong ^a   Wang, Yingcheng ^a   Wang, Jia ^a   Xiang, Bo ^a   Wu, Junyao ^a   Deng, Wei ^a   Li, Mingli ^a   Wang, Qiang ^a   Li, Tao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

APC gene; Depression; Pharmacogenetics; REEP5 gene; Treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; APC PROTEIN; CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADENOMATOUS POLYPOSIS COLI GENE; ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; RECEPTOR ACCESSORY PROTEIN 5 GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOMATOUS POLYPOSIS COLI; ADULT; ANTIDEPRESSIVE AGENTS; CHINA; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPING TECHNIQUES; HAPLOTYPES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84865359442     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.05.015     Document Type: Article

References (35)

1. Lopez-Leon S., Janssens A., Ladd A.M.G.Z., Del-Favero J., Claes S., Oostra B., et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 2007, 13:772-785.
2. Muglia P., Tozzi F., Galwey N., Francks C., Upmanyu R., Kong X., et al. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry 2008, 15:589-601.
3. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
4. Rush A.J. The varied clinical presentations of major depressive disorder. J Clin Psychiatry 2007, 68:4.
5. Spoletini I., Gianni W., Repetto L., Bria P., Caltagirone C., Boss P., et al. Depression and cancer: an unexplored and unresolved emergent issue in elderly patients. Crit Rev Oncol Hematol 2008, 65:143-155.
6. Irie M., Miyata M., Kasai H. Depression and possible cancer risk due to oxidative DNA damage. J Psychiatr Res 2005, 39:553-560.
7. Akechi T., Okuyama T., Sugawara Y., Nakano T., Shima Y., Uchitomi Y. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 2004, 22:1957.
8. Grassi L., Travado L., Moncayo F.L.G., Sabato S., Rossi E. Psychosocial morbidity and its correlates in cancer patients of the Mediterranean area: findings from the Southern European Psycho-Oncology Study. JAffect Disord 2004, 83:243-248.
9. Breitbart W., Rosenfeld B., Pessin H., Kaim M., Funesti-Esch J., Galietta M., et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000, 284:2907.
10. Sellick S.M., Crooks D.L. Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions. Psychooncology 1999, 8:315-333.
11. Massie M.J. Prevalence of depression in patients with cancer. JNCI Monographs 2004, 57.
12. Lydiatt W., Moran J., Burke W.J. A review of depression in the head and neck cancer patient. Clin Advances in Hema Onco 2009, 7:397-402.
13. Cui D., Jiang K., Jiang S., Xu Y., Yao H. The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia. Mol Psychiatry 2005, 10:669-677.
14. Schneikert J., Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007, 56:417.
15. Pleasure S.J. An arrow hits the Wnt signaling pathway. Trends Neurosci 2001, 24:69-71.
16. Ferrero A., Cereseto M., Sifonios L. The relationship between the Wnt signaling and the psychiatric diseases. Vertex (Buenos Aires, Argentina) 2006, 17:165.
17. Inkster B., Nichols T.E., Saemann P.G., Auer D.P., Holsboer F., Muglia P., et al. Pathway-based approaches to imaging genetics association studies: Wnt signaling, GSK3beta substrates and major depression. Neuroimage 2010, 53:908-917.
18. Beasley C., Cotter D., Everall I. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr Res 2002, 58:63-67.
19. Voeltz G.K., Prinz W.A., Shibata Y., Rist J.M., Rapoport T.A. A class of membrane proteins shaping the tubular endoplasmic reticulum. Cell 2006, 124:573-586.
20. Lesch K.P., Timmesfeld N., Renner T.J., Halperin R., Röser C., Nguyen T.T., et al. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. J Neural Transm 2008, 115:1573-1585.
21. Renner T., Gerlach M., Romanos M., Herrmann M., Reif A., Fallgatter A., et al. Neurobiology of attention-deficit hyperactivity disorder. Der Nervenarzt 2008, 79:771.
22. Jacob C.P., Romanos J., Dempfle A., Heine M. Comorbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci 2007, 257:309-317.
23. First M., Spitzer R.L., Gibbon M., Williams J.B. Structured clinical interview for DSM-IV axis I disorders-patient edition (SCID-I/P, version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967.
25. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E., et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003, 361:653-661.
26. Ban J.Y., Kim S.K., Kim H.J., Chung J.H., Kim T., Park J.K., et al. Association between interleukin 31 receptor a gene polymorphism and schizophrenia in Korean population. The Korean Journal of Physiology & Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology 2008, 12:205.
27. Marija J., Norušis S.I. SPSS 12.0 guide to data analysis. Prentice Hall 2004, 637.
28. Straub R., MacLean C., O'Neill F., Walsh D., Kendler K. Support for a possible schizophrenia vulnerability locus in region 5q22-31 in Irish families. Mol Psychiatry 1997, 2:148.
29. Reiche E.M.V., Nunes S.O.V., Morimoto H.K. Stress, depression, the immune system, and cancer. Lancet Oncol 2004, 5:617-625.
30. Su L.K., Vogelstein B., Kinzler K.W. Association of the APC tumor suppressor protein with catenins. Science 1993, 262:1734.
31. Matsumine A., Ogai A., Senda T., Okumura N., Satoh K., Baeg G.H., et al. Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 1996, 272:1020.
32. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
33. Park S.H., Zhu P.P., Parker R.L., Blackstone C. Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. J Clin Invest 2010, 120:1097.
34. Catts V.S., Catts S.V. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?. Schizophr Res 2000, 41:405-415.
35. Cohen M.E., Dembling B., Schorling J.B. The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res 2002, 57:139-146.